Omeza, LLC
Omeza is a skin health company dedicated to restoring skin integrity for people with serious skin problems and optimizing skin quality for all. They develop marine-based products, including the OCM™ wound matrix, to support all phases of wound healing, reduce biofilm formation, decrease inflammation, increase tissue proliferation, and support skin remodeling. Their mission is to deliver complete wound care simply and effectively, aiming to prevent costly hospital admissions and amputations associated with chronic wounds.
Industries
Nr. of Employees
small (1-50)
Patents
Topical composition comprised of cod liver oil for treating wounds and skin disorders
US-12186346-B2
View DetailsTopical composition comprised of cod liver oil for treating wounds and skin disorders
US-12186347-B2
View DetailsTopical composition comprised of cod li [[ ]]ver oil for treating wounds and skin disorders
US-11903977-B2
View Details
Topical composition comprised of cod liver oil for treating wounds and skin disorders
US-12186346-B2
View DetailsTopical composition comprised of cod liver oil for treating wounds and skin disorders
US-12186347-B2
View DetailsTopical composition comprised of cod li [[ ]]ver oil for treating wounds and skin disorders
US-11903977-B2
View DetailsProducts
Acellular peptide-based wound matrix (single-use vial)
An absorbable, conformable acellular wound matrix formulated with marine-derived peptides and pharmaceutical-grade components, intended for weekly clinician-administered application to chronic, non-healing wounds.
Acellular peptide-based wound matrix (single-use vial)
An absorbable, conformable acellular wound matrix formulated with marine-derived peptides and pharmaceutical-grade components, intended for weekly clinician-administered application to chronic, non-healing wounds.
Services
Designs and runs randomized, open-label, multi-center and real-world clinical studies to evaluate wound-healing performance and secondary endpoints.
Training programs and materials for clinicians and distributor sales teams to support point-of-care application and product integration into outpatient workflows.
National commercialization, logistics, ordering, and customer service provided through an exclusive distribution partner for outpatient settings and federal channels.
Engagement pathways for reimbursement and payor communication, including dedicated resources for federal customers (VA, DOD, IHS).
Designs and runs randomized, open-label, multi-center and real-world clinical studies to evaluate wound-healing performance and secondary endpoints.
Training programs and materials for clinicians and distributor sales teams to support point-of-care application and product integration into outpatient workflows.
National commercialization, logistics, ordering, and customer service provided through an exclusive distribution partner for outpatient settings and federal channels.
Engagement pathways for reimbursement and payor communication, including dedicated resources for federal customers (VA, DOD, IHS).
Expertise Areas
- Regenerative skin and wound care
- Clinical trial management for wound therapies
- Biomaterial formulation and productization
- Analytical testing and lab-based evaluation
Key Technologies
- Acellular peptide-based wound matrix
- Marine-derived peptide formulations
- Absorbable conformable wound matrices
- Randomized controlled trial and real-world study methodologies
News & Updates
Omeza will be attending the upcoming Symposium on Advanced Wound Care (SAWC) Fall 2025, September 4-6, 2025, alongside their national distributor, Advanced Solution.
Advanced Solution and Omeza Holdings Inc. announced an exclusive national commercialization partnership for Omeza’s OCMTM, aiming to expand access to wound care solutions nationwide.
Clinical data shows that weekly treatment with Omeza’s OCM™ resulted in 90-100% wound closure at 12 weeks in patients with diabetic foot ulcers.
Omeza was awarded the Top Innovation in Wound Care 2022 by Wound Management & Prevention Journal for their product bundle.
Omeza will be attending the upcoming Symposium on Advanced Wound Care (SAWC) Fall 2025, September 4-6, 2025, alongside their national distributor, Advanced Solution.
Advanced Solution and Omeza Holdings Inc. announced an exclusive national commercialization partnership for Omeza’s OCMTM, aiming to expand access to wound care solutions nationwide.
Clinical data shows that weekly treatment with Omeza’s OCM™ resulted in 90-100% wound closure at 12 weeks in patients with diabetic foot ulcers.
Omeza was awarded the Top Innovation in Wound Care 2022 by Wound Management & Prevention Journal for their product bundle.